Libourne 20th July 2016- Consolidated sales of the Ceva Group reached €455m at the end of June 2016, representing growth of 7% versus last year +13% at a constant perimeter and exchange rates.
Sales grew in all zones, except Latin America, which was stable versus last year (despite significant negative currency impact), with strong performance in Asia (+31%) and Europe (+13%).
All species are growing, especially Poultry (+12% global) and Swine (+11%).
The group delivered an operational result ahead of its budgeted objective and continued to make significant investments in R&D (c.10% of sales) and production sites around the world.
Dr. Marc Prikazsky, Ceva’s Chairman and CEO commented, “The organic growth of the group remains consistent and ahead of our 2020 business plan. Additionally, we made three strategic acquisitions in the last 6 months: iD Projects (hatchery automation and equipment), Polchem (geo-expansion in India) and Biovac (autogenous vaccines). It’s very pleasing to see our attractiveness to other top talented teams, who have chosen to join our success story. We continue to invest in our people, plants and our product pipeline, in order to fuel our virtuous circle of profitable growth.”
About Ceva Santé Animale:
Ceva Santé Animale was founded in 1999 and is a global veterinary health company, focused on research, development, production and marketing of pharmaceutical products and vaccines for companion animals, livestock, swine and poultry. Its headquarters are in Libourne (Gironde).
Ceva Chairman and CEO is Marc Prikazsky.
>> Download the PDF version:
Related topics: results